Naslov
Stable Pentadecapeptide BPC 157 and Vesicovaginal Fistulas in Rats

Autori
Rasic, Domagoj ; Sever, Marko ; Sever, Anita Zenko ; Pavlov, Katarina Horvat ; Baric, Marko ; Drmic, Domagoj ; Blagaic, Alenka Boban ; Seiwerth, Sven ; Sikiric, Predrag

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
FASEB Journal. 2018 ; 32(S1) / - : John Wiley & Sons, 2018, 83215-83215

Skup
Experimental Biology

Mjesto i datum
San Diego (CA), Sjedinjene Američke Države, 21.04.2018. - 25.04.2018

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
BPC 157 ; vesicovaginal fistula

Sažetak
Aim Frequently, large vesicovaginal fistulas need operation treatment. Stable gastric pentadecapeptide BPC 157, tested in clinical trials for ulcerative colitis therapy and now multiple sclerosis (Curr Pharm Des. 2017 ; 23(27):4012–4028 ; Curr Pharm Des. 2014 ; 20(7):1126–35 ; Curr Pharm Des. 2010 ; 16(10):1224–34), already resolved the healing of various fistulas (Eur J Pharmacol. 2016 Jun 5 ; 780:1–7 ; Life Sci. 2016 Mar 1 ; 148:63–70 ; J Physiol Pharmacol. 2015 Aug ; 66(4):581–90 ; Eur J Pharmacol. 2013 Feb 15 ; 701(1–3):203–12 ; J Pharmacol Sci. 2008 Sep ; 108(1):7–17 ; Dig Dis Sci. 2009 Jan ; 54(1):46–56). Thus, BPC 157 may be a successful therapy of vesicovaginal fistulas in rats. Methods Vesicovaginal fistulas were created in Wistar rats. The vesicovaginal fistula was surgically created (4mm length between posterior wall of the urinary bladder and anterior vaginal wall ). Medication. Pentadecapaptide BPC 157 (10 μg/kg/day, 10ng/kg/day) was given intraperitoneally (5 ml/kg) or in drinking water (0.16 μg/ml, 0.16 ng/ml, 12 ml/rat/day) while controls received equivolume of saline or drinking water only. Assessment (the pressure required for leakage of fluid through fistula (mLH2O), diameter of the fistula defects (mm) (bladder, vaginal side), macro/microscopical evaluation, urinary stone presentation) was 1, 2, 3, 4, and 6 weeks. Prophylactic regimen. Medication was started immediately after fistulas creation. Therapy regimen. Medication was initiated with already advanced fistula formation, after 2 weeks. Results Unlike poor healing in controls, BPC 157 reduced fistulas diameters (7th day) leading to the complete closure at 46th day and considerable volume needed to leakage of fluid through fistula (V: 5.3+/−0.3 mL). Finally, the fistula was successfully healed and microscopically confirmed in BPC 157 rats (day 46, 0+/−0 mm (diameter, bladder/vagina), unlike open defects in controls: 3.1+/−0.6 (mm, bladder), 3.3+/−0.8 (mm, vagina)) diameter and small volume sustained before leakage (V: 1.2+/−0.4 mL, day 14). In posttreatment BPC 157 group we noticed reducing of fistula diameter since a first posttreatment week ( con 3.8 +/−0.2 mm, BPC 157 3.1 +/−0.1 mm) leading to fistula closing during the 4th posttreatment week. In all control animals, we noticed urinary bladder stone creation which was absent in BPC 157 animals. In posttreatment animals, BPC 157 (therapy regimen) stopped further urinary stone creation. Conclusion Pentadecapeptide BPC 157 improved vesicovaginal fistula healing, and it could be the pharmacological solution for the complex clinical problem of vesicovaginal fistulas healing. Vesicovaginal fistula could be used as a urinary stone animal model. BPC157 reduces urinary stone creation.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti

POVEZANOST RADA